9.13
price down icon3.79%   -0.36
after-market After Hours: 9.13
loading

Amicus Therapeutics Inc Stock (FOLD) Latest News

pulisher
06:07 AM

Y Intercept Hong Kong Ltd Purchases 85,951 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

06:07 AM
pulisher
Feb 28, 2025

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - GlobeNewswire

Feb 28, 2025
pulisher
Feb 27, 2025

HealthInvest Partners AB Has $3.08 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

State of New Jersey Common Pension Fund D Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Feb 26, 2025
pulisher
Feb 25, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Transcend Capital Advisors LLC - MarketBeat

Feb 25, 2025
pulisher
Feb 24, 2025

Wells Fargo & Company Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00 - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat

Feb 23, 2025
pulisher
Feb 23, 2025

Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey

Feb 23, 2025
pulisher
Feb 23, 2025

Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to Hold at StockNews.com - MarketBeat

Feb 23, 2025
pulisher
Feb 23, 2025

Amicus Therapeutics (NASDAQ:FOLD) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat

Feb 23, 2025
pulisher
Feb 22, 2025

Amicus Therapeutics (FOLD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat

Feb 22, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics files prospectus for stock sales By Investing.com - Investing.com Australia

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call Transcript - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics CEO Campbell Bradley sells $4,000 in stock - Investing.com India

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics files prospectus for stock sales - Investing.com India

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Peregrine Capital Management LLC - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics (NASDAQ:FOLD) Stock Quotes, Forecast and News Summary - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

Form 424B5 AMICUS THERAPEUTICS, - StreetInsider.com

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lifted by Rice Hall James & Associates LLC - MarketBeat

Feb 21, 2025
pulisher
Feb 21, 2025

Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

Amicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy Changes - TipRanks

Feb 21, 2025
pulisher
Feb 20, 2025

Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates - MSN

Feb 20, 2025
pulisher
Feb 20, 2025

Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics - MSN

Feb 20, 2025
pulisher
Feb 20, 2025

Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing Earnings - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Amicus projects 17%-24% revenue growth in 2025, fueled by Fabry and Pompe therapies - MSN

Feb 20, 2025
pulisher
Feb 20, 2025

Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Amicus Therapeutics: From Strong Growth to Exciting Future Projections - Jomfruland.net

Feb 20, 2025
pulisher
Feb 19, 2025

Amicus Therapeutics Inc FOLD - Stockhouse Publishing

Feb 19, 2025
pulisher
Feb 19, 2025

BofA cuts Amicus Therapeutics stock target to $14, keeps Buy rating - Investing.com Canada

Feb 19, 2025
pulisher
Feb 19, 2025

AMICUS THERAPEUTICS, INC. SEC 10-K Report - TradingView

Feb 19, 2025
pulisher
Feb 19, 2025

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm - Milton Daily Standard

Feb 19, 2025
pulisher
Feb 19, 2025

AMICUS THERAPEUTICS Earnings Results: $FOLD Reports Quarterly Earnings - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Amicus Therapeutics Turns To Q4 Profit; Product Sales Grow 30% - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Amicus Therapeutics' Q4 Non-GAAP Earnings, Net Product Revenue Rise -February 19, 2025 at 07:34 am EST - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Amicus Therapeutics Reports Strong 2024 Financial Results and Positive Outlook for 2025 - TradingView

Feb 19, 2025
pulisher
Feb 19, 2025

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates - GlobeNewswire

Feb 19, 2025
pulisher
Feb 19, 2025

BRIEF-Amicus Therapeutics Q4 Net Income USD 14.7 Million - TradingView

Feb 19, 2025
pulisher
Feb 19, 2025

Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

Feb 19, 2025
pulisher
Feb 18, 2025

Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Amicus Therapeutics FY 2024 Earnings Preview - MSN

Feb 18, 2025
$76.29
price down icon 6.45%
$22.96
price up icon 1.23%
$33.86
price up icon 0.65%
$19.13
price down icon 7.54%
biotechnology ONC
$245.53
price down icon 9.67%
$111.56
price down icon 1.20%
Cap:     |  Volume (24h):